# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cybin Inc. (NEO:CYBN) (NYSE:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing Psychedelics t...
This article was originally published on Psychedelic Spotlight and appears here with permission. It’s yet another sign that th...
Last Week In Psychedelics:
Contents
Atai Life Sciences Launches New Salvia Divinorum Subsidiary Atai Life Sciences (NASDAQ: ATAI) announced the launch of a new su...
Psychedelics ETFs Are Gaining Traction Defiance ETFs launched the “Next Gen Altered Experience ETF,” the first U.S.-listed ETF...